Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tencent Music Entertainment Group - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Tencent Music Entertainment Group - ADR trades at $8.85 (market cap $14.63B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays a 2.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TME | |
|---|---|---|
Market Cap | $39.89B | $14.63B |
Sector | Health | Media |
52-Week High | $491.22 | $26.36 |
52-Week Low | $278.09 | $8.16 |
Enterprise Value | $38.15B | $11.41B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TME trades at $8.88, up 0.34% today, with a bullish technical signal despite recent earnings misses. The stock shows strong fundamentals with a P/E of 10.63 and net income margin of 26.48% for 2025. Revenue grew to $32.90B in 2025, though Q2 2026 EPS is expected at $0.24. Analyst consensus is mixed with a $14.00 price target. Recent news highlights strategic moves like the Ximalaya acquisition and partnerships, though competition remains a concern.
The outlook for TME is cautiously optimistic with solid profitability and valuation support, but near-term growth faces headwinds from competition and AI-related challenges. Investors should weigh the attractive margins against execution risks and market sentiment shifts for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
